Edesa Biotech Inc. (EDSA)
NASDAQ: EDSA
· Real-Time Price · USD
2.03
-0.02 (-0.98%)
At close: Jun 30, 2025, 3:59 PM
1.97
-2.96%
After-hours: Jun 30, 2025, 07:47 PM EDT
Company Description
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs.
Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis.
It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10.
Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Edesa Biotech Inc.
| Country | CA |
| IPO Date | Jun 21, 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Pardeep Nijhawan FRCPC, |
Contact Details
Address: 100 Spy Court Markham, ON CA | |
| Website | https://www.edesabiotech.com |
Stock Details
| Ticker Symbol | EDSA |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001540159 |
| CUSIP Number | 27966L108 |
| ISIN Number | CA27966L3065 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Pardeep Nijhawan FRCPC, M.D. | Chief Executive Officer, Company Secretary & Director |
| Peter John Weiler M.B.A, M.Sc. | Chief Financial Officer |
| Dr. Michael J. Brooks M.B.A., Ph.D. | President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 02, 2025 | 4 | Filing |
| Jun 02, 2025 | 4 | Filing |
| Jun 02, 2025 | 4 | Filing |
| Jun 02, 2025 | 4 | Filing |
| Jun 02, 2025 | 4 | Filing |
| Jun 02, 2025 | 4 | Filing |
| Jun 02, 2025 | 4 | Filing |
| Jun 02, 2025 | 4 | Filing |
| Jun 02, 2025 | 4 | Filing |
| May 28, 2025 | S-8 | Filing |